Literature DB >> 24237365

Detection of factor XIII-A is a valuable tool for distinguishing dendritic cells and tissue macrophages in granuloma annulare and necrobiosis lipoidica.

D Töröcsik1, H Bárdos, Zs Hatalyák, B Dezső, G Losonczy, L Paragh, Z Péter, M Balázs, E Remenyik, R Adány.   

Abstract

BACKGROUND: Factor XIII subunit A (FXIII-A) is used as a diagnostic marker in a wide range of dermatological diseases ranging from inflammatory lesions to malignancies, although neither the cell types responsible for its expression nor the mechanism(s) resulting in its local accumulation in pathological conditions have been characterized.
OBJECTIVE: In this study, we aimed to gain information on the cells showing an immunohistochemical reaction for FXIII-A and answer the question whether macrophages and/or dendritic cells are labelled for FXIII-A.
METHODS: We carried out our studies on samples of granuloma annulare (GA) and necrobiosis lipoidica (NL), the prime examples for granulomatous skin lesions with a non-infectious background in which extracellular matrix remodelling is a key feature without any sign of malignant transformation. We used markers for macrophages and dendritic cells in combination with the detection of FXIII-A in double labelling immunohistochemical reactions.
RESULTS: We demonstrated that FXIII-A positivity clearly distinguishes macrophages (CD163+/FXIII-A+) from dendritic cells (CD11c+/FXIII-A-) not only in the normal dermis as previously described by Zaba et al. (J Clin Invest 2007; 117: 2517-2525) but also in the pathological conditions of GA and NL. Detecting the expression of DC-SIGN/CD209 and mannose receptor molecules on FXIII-A+ macrophages we confirmed that FXIII-A is expressed in the alternatively activated macrophages. However, while DC-SIGN/CD209 was invariably expressed on FXIII-A+ cells both in normal and pathological conditions of GA/NL (98.7% vs. 93.5/96%), mannose receptor was only partially coexpressed with FXIII-A (94.8% vs. 74.7/52.2%), suggesting that FXIII-A+ macrophages do not represent a homogenous population.
CONCLUSIONS: FXIII-A selectively marks macrophages and distinguishes them from dendritic cells. The presence of FXIII-A is not a disease-specific marker but indicates a possible common mechanism of macrophage activation in various dermatological diseases.
© 2013 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24237365     DOI: 10.1111/jdv.12290

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  5 in total

1.  Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes.

Authors:  Christoffer Soendergaard; Peter Helding Kvist; Jakob Benedict Seidelin; Hermann Pelzer; Ole Haagen Nielsen
Journal:  J Gastroenterol       Date:  2015-12-11       Impact factor: 7.527

Review 2.  Dendritic Cell Subsets in Asthma: Impaired Tolerance or Exaggerated Inflammation?

Authors:  Heleen Vroman; Rudi W Hendriks; Mirjam Kool
Journal:  Front Immunol       Date:  2017-08-09       Impact factor: 7.561

3.  The C-Type Lectin Receptor DC-SIGN Has an Anti-Inflammatory Role in Human M(IL-4) Macrophages in Response to Mycobacterium tuberculosis.

Authors:  Geanncarlo Lugo-Villarino; Anthony Troegeler; Luciana Balboa; Claire Lastrucci; Carine Duval; Ingrid Mercier; Alan Bénard; Florence Capilla; Talal Al Saati; Renaud Poincloux; Ivanela Kondova; Frank A W Verreck; Céline Cougoule; Isabelle Maridonneau-Parini; Maria Del Carmen Sasiain; Olivier Neyrolles
Journal:  Front Immunol       Date:  2018-06-12       Impact factor: 7.561

4.  Perforating Granuloma Annulare - An Unusual Subtype of a Common Disease.

Authors:  João Alves; Hugo Barreiros; Elvira Bártolo
Journal:  Healthcare (Basel)       Date:  2014-09-04

Review 5.  Factor XIII Subunit A in the Skin: Applications in Diagnosis and Treatment.

Authors:  Lilla Paragh; Daniel Törőcsik
Journal:  Biomed Res Int       Date:  2017-08-15       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.